Mr. Ed Field, Chief Operating Officer at Aldagen, explains the principles behind ALDEFLUOR™-based detection of ALDH bright cells and discusses evidence demonstrating ALDH’s potential as a biomarker for cancer stem cell characterization and tumor prognosis.
June 25, 2015
Request Webinar Form
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
. Please contact us
with any questions that you may have. You can unsubscribe or change your email preferences
at any time.